RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 157 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 0.96 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,943,262 | -70.8% | 907,616 | -71.4% | 0.04% | -68.4% |
| Q2 2023 | $23,740,997 | -26.2% | 3,178,179 | -34.1% | 0.13% | -39.3% |
| Q1 2023 | $32,187,653 | -13.5% | 4,825,735 | 0.0% | 0.22% | +25.9% |
| Q4 2022 | $37,206,417 | -23.8% | 4,825,735 | +5.2% | 0.17% | -39.6% |
| Q3 2022 | $48,809,000 | +30.7% | 4,587,274 | 0.0% | 0.29% | -50.1% |
| Q2 2022 | $37,341,000 | +13.7% | 4,587,274 | 0.0% | 0.58% | +43.5% |
| Q1 2022 | $32,845,000 | -51.1% | 4,587,274 | +16.9% | 0.40% | -40.9% |
| Q4 2021 | $67,213,000 | -25.6% | 3,923,713 | 0.0% | 0.68% | +78.9% |
| Q3 2021 | $90,285,000 | -35.9% | 3,923,713 | +1.7% | 0.38% | -51.4% |
| Q2 2021 | $140,839,000 | – | 3,858,617 | – | 0.78% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CRV, LLC | 733,986 | $16,889,000 | 37.30% |
| MIC CAPITAL PARTNERS (PUBLIC) (US) IM, LLC | 1,388,889 | $31,958,000 | 5.87% |
| Yong Rong (HK) Asset Management Ltd | 377,000 | $8,675,000 | 5.69% |
| Samsara BioCapital, LLC | 752,939 | $17,325,000 | 2.72% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $34,728,000 | 2.04% |
| Spouting Rock Asset Management, LLC | 52,851 | $1,216,000 | 0.61% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 661,703 | $15,226,000 | 0.43% |
| Laurion Capital Management LP | 3,923,713 | $90,285,000 | 0.38% |
| Casdin Capital, LLC | 548,156 | $12,613,000 | 0.31% |
| Baillie Gifford | 22,061,374 | $507,632,000 | 0.27% |